Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Emory University, Atlanta, GA, United States

Survival: 13.0 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: Atlanta, GA
Hospital: Emory University
Journal: Link
Date: 1/2010

In this study, patients with advanced non-small-cell lung cancer were divided into two treatment groups. Group A consisted of 62 patients with a median age of 64 years, 61% of whom were male. Group B had 32 patients with a median age of 66.5 years, 63% of whom were male.

Patients in group A received a combination of three chemotherapy agents: carboplatin, paclitaxel, and vorinostat. Patients in group B were given carboplatin, paclitaxel, and a placebo.

There were 2 treatment-related deaths in group A, one due to infection/neutropenia, the other due to an undetermined cause. Other toxicities in this group included grade 3-4 low platelet count and neutropenia, as well as grade 2 nausea, fatigue and alopecia.

The maximum toxicity reported for group B was of grade 4. Grade 3-4 adverse events included low platelets, neutropenia, and leucopenia.

The median overall survival for group A was 13.0 months. For group B, the median overall survival was 9.7 months.

One of the authors has received funding from Merck, makers of vorinostat.

Correspondence: Dr. Suresh S. Ramalingam; email:

E-mail to a Friend Email Physician More Information